132 related articles for article (PubMed ID: 36096460)
1. Molecular pathways in periampullary cancer: An overview.
Apurva ; Abdul Sattar RS; Ali A; Nimisha ; Kumar Sharma A; Kumar A; Santoshi S; Saluja SS
Cell Signal; 2022 Dec; 100():110461. PubMed ID: 36096460
[TBL] [Abstract][Full Text] [Related]
2. Identification of PI3K-AKT signaling as the dominant altered pathway in intestinal type ampullary cancers through whole-exome sequencing.
Kumari N; Singh RK; Mishra SK; Krishnani N; Mohindra S; L R
J Pathol Transl Med; 2021 May; 55(3):192-201. PubMed ID: 33677956
[TBL] [Abstract][Full Text] [Related]
3. Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview.
Sikdar N; Saha G; Dutta A; Ghosh S; Shrikhande SV; Banerjee S
Curr Genomics; 2018 Sep; 19(6):444-463. PubMed ID: 30258276
[TBL] [Abstract][Full Text] [Related]
4. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
6. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
[TBL] [Abstract][Full Text] [Related]
7. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Fang B
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):27-38. PubMed ID: 26350096
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
Wang J; Li R; He Y; Yi Y; Wu H; Liang Z
Mod Pathol; 2020 Dec; 33(12):2591-2601. PubMed ID: 32620917
[TBL] [Abstract][Full Text] [Related]
9. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
Hu HF; Ye Z; Qin Y; Xu XW; Yu XJ; Zhuo QF; Ji SR
Acta Pharmacol Sin; 2021 Nov; 42(11):1725-1741. PubMed ID: 33574569
[TBL] [Abstract][Full Text] [Related]
10. Mathematical modeling the order of driver gene mutations in colorectal cancer.
Li L; Hu Y; Xu Y; Tang S
PLoS Comput Biol; 2023 Jun; 19(6):e1011225. PubMed ID: 37368936
[TBL] [Abstract][Full Text] [Related]
11. Identification and prevalence of potentially therapeutic targetable variants of major cancer driver genes in ampullary cancer patients in India through deep sequencing.
Mishra SK; Kumari N; Krishnani N; Singh RK; Mohindra S
Cancer Genet; 2021 Nov; 258-259():41-48. PubMed ID: 34455261
[TBL] [Abstract][Full Text] [Related]
12. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of KRAS signaling in pancreatic cancer is not associated with
Lemstrova R; Brynychova V; Hughes DJ; Hlavac V; Dvorak P; Doherty JE; Murray HA; Crockard M; Oliverius M; Hlavsa J; Honsova E; Mazanec J; Kala Z; Lovecek M; Havlik R; Ehrmann J; Strouhal O; Soucek P; Melichar B; Mohelnikova-Duchonova B
Oncol Lett; 2017 Nov; 14(5):5980-5988. PubMed ID: 29113235
[TBL] [Abstract][Full Text] [Related]
14. Frequency of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling pathway pathogenic alterations in EUS-FNA sampled malignant lymph nodes in rectal cancer with theranostic potential.
Gleeson FC; Kipp BR; Voss JS; Campion MB; Minot DM; Tu ZJ; Klee EW; Graham RP; Lazaridis KN; Henry MR; Levy MJ
Gastrointest Endosc; 2015 Sep; 82(3):550-6.e1. PubMed ID: 25887718
[TBL] [Abstract][Full Text] [Related]
15. Mutational Landscape in Resected Periampullary Adenocarcinoma: Relationship With Morphology and Clinical Outcome.
Lundgren S; Hau SO; Elebro J; Heby M; Karnevi E; Nodin B; Eberhard J; Holm K; Staaf J; Jönsson GB; Jirström K
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914025
[TBL] [Abstract][Full Text] [Related]
16. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
17. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
18. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
Yip WK; Choo CW; Leong VC; Leong PP; Jabar MF; Seow HF
APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA profiling in periampullary carcinoma.
Kalluri Sai Shiva UM; Kuruva MM; Mitnala S; Rupjyoti T; Guduru Venkat R; Botlagunta S; Kandagaddala R; Siddapuram SP; Sekaran A; Chemalakonda R; Rebala P; Duvvuru NR
Pancreatology; 2014; 14(1):36-47. PubMed ID: 24555977
[TBL] [Abstract][Full Text] [Related]
20. Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas.
Bläker H; Helmchen B; Bönisch A; Aulmann S; Penzel R; Otto HF; Rieker RJ
Scand J Gastroenterol; 2004 Aug; 39(8):748-53. PubMed ID: 15513360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
